ArticleThe British journal of dermatology2020
Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP).
Article in The British journal of dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Topical Anti-Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta-Analysis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2024Pooled it
- Educational and psychological interventions for managing atopic dermatitis (eczema).The Cochrane database of systematic reviews · 2024Pooled it
- Topical anti-inflammatory treatments for eczema: network meta-analysis.The Cochrane database of systematic reviews · 2024Pooled it
- Phototherapy for atopic eczema.The Cochrane database of systematic reviews · 2021Pooled it
- Long-term Progressive Improvement of Atopic Dermatitis by an Herbal Emollient Plus Combination in a 12-week Clinical Trial.Acta dermato-venereologica · 2025Trial
- Comparison of lotions, creams, gels and ointments for the treatment of childhood eczema: the BEE RCT.Health technology assessment (Winchester, England) · 2023Trial
- Eczema Care Online behavioural interventions to support self-care for children and young people: two independent, pragmatic, randomised controlled trials.BMJ (Clinical research ed.) · 2022Trial
- Trial
- Trial of food allergy IgE tests for Eczema Relief (TIGER): study protocol.Skin health and disease · 2026Article
- Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis.Acta dermato-venereologica · 2026Article
- Retrospective Assessment of Social Rejection Related to Atopic Dermatitis During Childhood and Adolescence: The Scars of Life-Eczema Study.International journal of dermatology · 2026Article
- Atopic dermatitis.Nature reviews. Disease primers · 2026Review
- Article
- Defining "Flares" in Atopic Dermatitis: A Narrative Review.American journal of clinical dermatology · 2025Review
- Assessing Atopic Dermatitis Control in Chinese Patients: Validation of the Chinese Version of Recap of Atopic Eczema Questionnaire (RECAP) and an Investigation into Its Interpretability.Acta dermato-venereologica · 2025Article
- Impact of Long-term Stability on Mental Health in Adults with Atopic Dermatitis: A Cohort Study with Unsupervised Cluster Analysis.Acta dermato-venereologica · 2025Article
- CF Tummy Tracker: A Cystic Fibrosis-Specific Patient-Reported Outcome Measure for Daily Gastrointestinal Symptom Burden.Mayo Clinic proceedings. Digital health · 2025Article
- Validation of the Atopic Dermatitis Control Tool (ADCT) and a Comparison with the Recap of Atopic Eczema Questionnaire (RECAP).Acta dermato-venereologica · 2025Article
- Determining the minimal important change of the recap of atopic eczema (RECAP) instrument in clinical trials.Skin health and disease · 2024Article
- Cost-Effectiveness of Dupilumab and Oral Janus Kinase Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis in Singapore.PharmacoEconomics - open · 2024Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 7 institutions in 4 countries.
Funding
Abstract
backgroundEczema control has been identified as an important outcome by key stakeholders in eczema research (including patients, carers, healthcare professionals and researchers) but no validated instruments for the domain have been identified.
objectivesTo develop a measurement instrument to capture a patient's perspective of eczema control that is suitable for use in eczema clinical trials.
methodsBest practice for the development of a patient-reported outcome was followed. A mixed-methods approach was used to develop and refine a conceptual framework, generate, refine and select items and to test the distribution and construct validity of the final scale. The mixed-methods approach involved expert panel meetings (including patient representatives, healthcare professionals and methodologists), and data collection using a focus group, cognitive interviews and an online survey with people with eczema and caregivers. Multivariable linear regression was used in the item selection process.
resultsFourteen expert panel members co-produced the instrument, with input from people with eczema and caregivers via a focus group (n = 6), cognitive interviews (n = 13) and an online survey (n = 330). The resulting instrument, Recap of atopic eczema (RECAP), is a seven-item questionnaire that captures eczema control via self or caregiver report. The development process aimed to ensure good content validity and feasibility. Initial testing suggested no floor or ceiling effects and good construct validity. Hypothesized correlation with the Patient-Oriented Eczema Measure was confirmed [r(258) = 0·83, P < 0·001].
conclusionsRECAP has the potential to improve reporting of eczema control in research and clinical practice. Further exploration of measurement properties is required. Linked Comment: Pattinson and Bundy. Br J Dermatol 2020; 183:418-419. What's already known about this topic? Eczema control has been identified as an important outcome by key stakeholders in eczema research (including patients, carers, healthcare professionals and researchers). Qualitative studies suggest eczema control is a multifaceted and individual experience and no instrument has been identified that captures eczema control in this way. What does this study add? We have developed Recap of atopic eczema (RECAP), a seven-item questionnaire to capture the experience of eczema control in all ages and eczema severities; there are two versions: a self-reported version for adults and older children with eczema, and a caregiver-reported version for younger children with eczema. Designed with input from people with eczema, caregivers and healthcare professionals to ensure good content validity. Initial testing of score distributions and construct validity suggests good measurement properties. What are the clinical implications of the work? The RECAP instrument is appropriate and feasible for measuring eczema control in clinical trials and may also be useful in routine practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.